Gastroesophageal reflux disease is a chronic disease that adversely affects health-related quality of life.
Dr Gerson and colleagues from California, America aimed to derive health state utilities for patients with chronic heartburn symptoms.
The researchers used a custom-designed computer program in order to elicit utilities with the time-tradeoff and standard-gamble techniques.
The team entered to the study patients with chronic (more than 6 months) symptoms of gastroesophageal reflux disease.
The investigative team performed 2 interviews in random sequence either initially on medications for heartburn that adequately controlled symptoms, or off medications for 1 week while the patient was symptomatic.
Data was collected by the team using visual-analog scales, quality of life in reflux and dyspepsia, and Gastrointestinal Symptom Rating Scale scores.
Data was collected using visual-analog scales, quality of life in reflux and Gastrointestinal Symptom Rating Scale scores |
|The American Journal of Gastroenterology|
Of 222 patients invited to participate, 158 (71%) patients (129 men, 29 women) completed the study.
The researchers noted that Barrett's esophagus was present in 40 (25%), erosive disease in 17 (11%), and 118 (74%) had comorbid conditions.
The mean utility ratings were 0.94 on medical therapy and 0.90 off medications for patients with reflux alone using time tradeoff, and 0.94 both on and off of antireflux medications with standard-gamble assessment.
In addition, the research team reported that mean time-tradeoff scores were also significantly lower off medications for patients with other comorbid conditions.
There was no significant difference between mean utility scores for patients with or without Barrett's esophagus or erosive disease.
Dr Gerson concluded, “Gastroesophageal reflux disease adversely affects health-related quality of life.”
“Time-tradeoff utility for patients with reflux disease is substantially higher when patients are on medication than off medications."